Phosphodiesterase-5 (PDE-5) inhibitors (tadalafil, vardenafil, and sildenafil) and Endothelin Receptor Antagonists (ERA) (bosentan, ambrisentan, and macitentan), both recommended for PAH and digital ulcers, had a similar trend in the 2010–2017 period. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.